A year in the life of German patients with COPD: The DACCORD observational study

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 1639-1646

  Buhl, Roland ^a   Criée, Carl Peter ^b   Kardos, Peter ^c   Vogelmeier, Claus ^d,e   Lossi, Nadine ^f   Mailänder, Claudia ^f   Worth, Heinrich ^g  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b Department of Anesthesiolgy and Intensive Care Medicine   (Germany)

^c Group Practice and Allergy   (Germany)

^d UNIVERSITY HOSPITAL GIESSEN   (Germany)

^e German Center for Infection Research   (Germany)

^f NOVARTIS PHARMA GMBH   (Germany)

^g Praxis Drs Bily Kellermann   (Germany)

Author keywords

COPD; COPD exacerbations; Epidemiology

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING BETA 2 AGONIST; LONG ACTING MUSCARINIC ANTAGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; BRONCHODILATING AGENT;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COPD ASSESSMENT TEST; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; GERMANIC PEOPLE; GERMANY; HIGH RISK PATIENT; HUMAN; LONGITUDINAL STUDY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE ASSESSMENT; DISEASE COURSE; DRUG EFFECTS; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; SECONDARY HEALTH CARE; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TIME FACTOR; TREATMENT OUTCOME;

AGED; BRONCHODILATOR AGENTS; DISEASE PROGRESSION; FORCED EXPIRATORY VOLUME; GERMANY; HUMANS; LONGITUDINAL STUDIES; LUNG; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SECONDARY CARE; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84982279491     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S112110     Document Type: Article

References (30)

1. Global Initiative for Chronic Obstructive Lung Disease [homepage on the Internet]. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2016. Available from: www.goldcopd.org. Accessed May 6, 2016.
2. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8): 775-789.
3. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15): 1543-1554.
4. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12): 1093-1103.
5. Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030): 1817-1826.
6. Punekar YS, Wurst K, Shukla A. Resource use and costs up to two years post diagnosis among newly diagnosed COPD patients in the UK primary care setting: a retrospective cohort study. COPD. 2015;12(3): 267-275.
7. James GD, Donaldson GC, Wedzicha JA, Nazareth I. Trends in management and outcomes of COPD patients in primary care, 2000-2009: a retrospective cohort study.. NPJ Prim Care Respir Med. 2014;24: 14015.
8. Ställberg B, Janson C, Johansson G, et al. Management, morbidity and mortality of COPD during an 11-year period: an observational retrospective epidemiological register study in Sweden (PATHOS). Prim Care Respir J. 2014;23(1): 38-45.
9. Kardos P, Vogelmeier C, Buhl R, Criée C-P, Worth H. The prospective non-interventional DACCORD Study in the National COPD Registry in Germany: design and methods. BMC Pulm Med. 2015;15(1): 2.
10. Mackay AJ, Donaldson GC, Patel ARC, Jones PW, Hurst JR, Wedzicha JA. Usefulness of the chronic obstructive pulmonary disease assessment test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med. 2012;185(11): 1218-1224.
11. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Physical activity and hospitalization for exacerbation of COPD. Chest. 2006;129(3): 536-544.
12. Solem CT, Sun SX, Sudharshan L, Macahilig C, Katyal M, Gao X. Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease.. Int J Chron Obstruct Pulmon Dis. 2013;8: 641-652.
13. Blasi F, Cesana G, Conti S, et al. The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLoS One. 2014;9(6): e101228.
14. Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ. 2011;14(3): 315-323.
15. Punekar YS, Shukla A, Müllerova H. COPD management costs according to the frequency of COPD exacerbations in UK primary care.. Int J Chron Obstruct Pulmon Dis. 2014;9: 65-73.
16. Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11): 957-963.
17. Uzaslan E, Mahboub B, Beji M, et al. The burden of chronic obstructive pulmonary disease in the Middle East and North Africa: results of the BREATHE study. Respir Med. 2012;106(suppl): S45-S59.
18. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med. 2002;96(9): 700-708.
19. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11): 925-931.
20. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12): 1128-1138.
21. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356): 449-456.
22. Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1(7): 524-533.
23. Cates C. Inhaled corticosteroids in COPD: quantifying risks and benefits. Thorax. 2013;68(6): 499-500.
24. Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013;42(3): 636-646.
25. Han MK, Muellerova H, Curran-Everett D, et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med. 2013;1(1): 43-50.
26. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012;186(10): 975-981.
27. Haughney J, Gruffydd-Jones K, Roberts J, Lee AJ, Hardwell A, McGarvey L. The distribution of COPD in UK general practice using the new GOLD classification. Eur Respir J. 2014;43(4): 993-1002.
28. Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3): 648-654.
29. Wurst KE, Punekar YS, Shukla A. Treatment evolution after COPD diagnosis in the UK primary care setting. PLoS One. 2014;9(9): e105296.
30. Penning-van Beest F, van Herk-Sukel M, Gale R, Lammers J-W, Herings R. Three-year dispensing patterns with long-acting inhaled drugs in COPD: a database analysis. Respir Med. 2011;105(2): 259-265.